Avelumab Doesn’t Improve Survival in Platinum-Refractory Ovarian Cancer
Cancer Therapy Advisor,
Treatment with avelumab, either alone or in combination, did not improve survival over standard therapy in patients with…
Treatment with avelumab, either alone or in combination, did not improve survival over standard therapy in patients with…
Moreover, corresponding median overall survival (OS) for each group was 15.7 months (95% CI, 12.7-18.7), 13.1 months (95% CI, 12.